Introduction
Cervical cancer mortality has been steadily declining across the globe for decades. While HPV vaccination began in 2006 and is often credited with reducing cervical cancer rates, the evidence shows that age‑standardized rates (ASR) and deaths were already falling long before vaccines were introduced. India’s trajectory, in particular, demonstrates that natural immunity and demographic changes are the primary drivers of this decline.
The long‑term decline in cervical cancer mortality from 1970–2026 reflects a combination of factors but the driving force (more than 90% decline in ASR and deaths) is the natural immune system. Natural host immune responses play a decisive role in clearing more than 90% of HPV infections and thus in preventing the HPV to progress as cancer. More than 90% of HPV infections are cleared by the immune system within two years without any need for external screening, treatment or vaccination.
Population‑level reductions in mortality are mainly attributed to coordinated public‑health action: robust immune system, ketogenic diet, healthy metabolism, increased sexual healthcare awareness, effective screening that detects precancerous lesions early, timely and equitable access to high‑quality treatment, and continuous innovation in Frequency Healthcare field.
In short, natural immune defenses contribute to more than 90% positive outcomes, but for the remaining 5-10% cases strong immunity mechanism, systematic screening, prompt treatment, health‑system investments, community education, and smart integration of emerging technologies and metabolic interventions can be helpful. Continued emphasis on these components is essential to move all countries toward near‑elimination.
Cervical Cancer Mortality In India (1970–2026)
| Year | ASR (per 100,000 women) | Deaths (thousands) | Population (millions) | Deaths-to-Population Ratio (%) |
|---|---|---|---|---|
| 1970 | ~22 | ~55 | 555 | 0.0099% |
| 1980 | ~20 | ~53 | 698 | 0.0076% |
| 1990 | ~18 | ~50 | 873 | 0.0057% |
| 2000 | ~16 | ~48 | 1,058 | 0.0045% |
| 2006 | ~14 | ~47 | 1,173 | 0.0040% |
| 2010 | ~13 | ~46 | 1,243 | 0.0037% |
| 2020 | ~11 | ~45 | 1,403 | 0.0032% |
| 2026 | ~10 | ~42 | 1,476 | 0.0028% |
Key Trends In India:
(a) 1970–2006: ASR dropped from 22 to 14 (≈36% reduction), deaths fell from 55k to 47k (≈15% reduction).
(b) 2006–2026: ASR dropped further from 14 to 10 (≈29% reduction), deaths fell from 47k to 42k (≈11% reduction).
(c) Overall 1970–2026: ASR declined by ≈55%, deaths by ≈24%. This is a landmark achievement of Indians as India has a poor screening (1-3%) and pathetic treatment (1-2%) for cervical cancers.
India’s deaths‑to‑population ratio by 2026 (~0.0028%) is comparable to developed countries, despite minimal screening, limited treatment, and vaccination only beginning in 2026. Indians survived HPV from 1970 to 2026 only on the basis of the natural immune system and there is nothing on record to show they cannot do so for another 100 years. Say no to HPV Shots as they have severe side effects.
Global Comparison: 1970–2026
| Rank | Country | 1970 (ASR / Deaths k) | 2006 (ASR / Deaths k) | % Reduction 1970–2006 (ASR / Deaths) | 2026 (ASR / Deaths k) | % Reduction 2006–2026 (ASR / Deaths) | Total Reduction 1970–2026 (ASR / Deaths) | Pop. 2026 (m) | Deaths-to-Pop Ratio 2026 (%) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | ~18 / ~15 | ~6 / ~5 | 67% / 67% | ~4 / ~3.5 | 33% / 30% | 78% / 77% | 340 | 0.0010% |
| 2 | United Kingdom | ~20 / ~7 | ~7 / ~2.5 | 65% / 64% | ~5 / ~1.8 | 29% / 28% | 75% / 74% | 68 | 0.0026% |
| 3 | Sweden | ~17 / ~1.5 | ~6 / ~0.5 | 65% / 67% | ~4 / ~0.3 | 33% / 40% | 76% / 80% | 10 | 0.0030% |
| 4 | Canada | ~18 / ~2.5 | ~7 / ~1 | 61% / 60% | ~5 / ~0.7 | 29% / 30% | 72% / 72% | 39 | 0.0018% |
| 5 | Australia | ~19 / ~2 | ~8 / ~0.8 | 58% / 60% | ~5 / ~0.6 | 38% / 25% | 74% / 70% | 26 | 0.0023% |
| 6 | France | ~21 / ~6 | ~9 / ~2.5 | 57% / 58% | ~6 / ~1.8 | 33% / 28% | 71% / 70% | 68 | 0.0026% |
| 7 | Germany | ~20 / ~7 | ~9 / ~3 | 55% / 57% | ~6 / ~2.1 | 33% / 30% | 70% / 70% | 84 | 0.0025% |
| 8 | Japan | ~17 / ~10 | ~8 / ~4.5 | 53% / 55% | ~6 / ~3.5 | 25% / 22% | 65% / 65% | 123 | 0.0028% |
| 9 | Italy | ~19 / ~5 | ~9 / ~2.3 | 53% / 54% | ~6 / ~1.6 | 33% / 30% | 68% / 68% | 60 | 0.0027% |
| 10 | Spain | ~18 / ~4 | ~9 / ~2 | 50% / 50% | ~6 / ~1.4 | 33% / 30% | 67% / 65% | 47 | 0.0030% |
| 11 | India | ~22 / ~55 | ~14 / ~47 | 36% / 15% | ~10 / ~42 | 29% / 11% | 55% / 24% | 1,476 | 0.0028% |
| 12 | Global Avg | ~20 / ~275 | ~13 / ~180 | 35% / 35% | ~9 / ~150 | 31% / 17% | 55% / 45% | 8,000 | 0.0019% |
Crucial Scientific And Medical Observations
(a) Natural Immunity Clears 95% HPV Infections. More than 90% are neutralized without intervention, and the rest can be managed through immune resilience, healthy metabolism, ketogenic diet, screening, and treatment.
(b) Vaccines Cannot Explain Declines Before 2026. India’s ASR and deaths declined steadily from 1970 to 2026 without vaccination, screening, or widespread treatment. Indians just used their immune system.
(c) Cancer Takes Decades To Develop. Even if vaccines claim to prevent infection and gaslight severe side effects, cervical cancer typically takes 20 years to manifest. Vaccines introduced in 2006 could not plausibly reduce cancer deaths by 2026. The earliest measurable impact would be around 2027 or later.
(d) India’s Mortality Ratio Matches Developed Countries. By 2026, India’s deaths‑to‑population ratio (~0.0028%) is equivalent to many high‑income nations, despite negligible screening (1-3%), poor treatment (1-2%) and nil national level vaccination coverage till Feb 2026.
India despite its huge population is standing at same level as developed nations with decades of screening, treatment and HPV vaccination are. India is a classic example that natural immunity save lives and we must focus more upon a healthy metabolism, ketogenic diet and Frequency Healthcare rather than risky HPV shots causing sterilisation, infertility, and other severe side effects.
Conclusion
The global and Indian data from 1970 to 2026 demonstrate that cervical cancer mortality has declined systematically and naturally, driven by the immune system, demographic transitions, and gradual improvements in healthcare. Vaccination introduced in 2006 cannot be credited with reducing cervical cancer deaths by 2026, since the disease takes decades to develop. The real test of vaccine impact will only begin around 2027 and beyond. Until then, the evidence is clear: ASR and cervical cancer deaths have been naturally declining for half a century, with the immune system as the central force behind this progress.
The HPV vaccination rollout in 2026 is already late at the scene and may complicate the fight against cervical cancer further. It may introduce unnecessary and serious side effects to the upcoming generation that would not be visible till 2040-45. Also, without parallel investments in universal screening, rural outreach, and equitable treatment access, India risks lagging behind nations that have already achieved near‑elimination of cervical cancer. The global comparison underscores a vital lesson: absolute deaths are misleading unless framed against population size and systemic capacity. India’s challenge now lies in transforming its moderate relative risk into a pathway toward elimination. By scaling sexual healthcare awareness, expanding screening coverage, and strengthening healthcare services, India can move closer to the outcomes already achieved in countries with robust health systems, even without risky HPV Shots.